These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30545999)

  • 1. Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?
    Weinberg BA
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1547-1548. PubMed ID: 30545999
    [No Abstract]   [Full Text] [Related]  

  • 2. Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.
    Kratz JD; Uboha NV; Lubner SJ; Mulkerin DL; Clipson L; Yi Y; Yu M; Matkowskyj KA; LoConte NK; Deming DA
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1442-1450. PubMed ID: 30545991
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumour location and efficacy of first-line EGFR inhibitors in
    Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
    ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential use of transrenal DNA for non-invasive monitoring and prognosis of colorectal cancer.
    Chen W; Liao Y; Yang C; Fang Z; Liu B; Zheng X; Zhou C
    Biomarkers; 2019 Sep; 24(6):524-529. PubMed ID: 31220949
    [No Abstract]   [Full Text] [Related]  

  • 5. EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer.
    Birkman EM; Avoranta T; Ålgars A; Korkeila E; Lintunen M; Lahtinen L; Kuopio T; Ristamäki R; Carpén O; Sundström J
    Hum Pathol; 2018 Dec; 82():163-171. PubMed ID: 30096327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
    De Cuyper A; Van Den Eynde M; Machiels JP
    Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
    Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
    Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
    Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
    Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.
    Tardito S; Matis S; Zocchi MR; Benelli R; Poggi A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
    Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
    J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
    Gbenedio OM; Bonnans C; Grun D; Wang CY; Hatch AJ; Mahoney MR; Barras D; Matli M; Miao Y; Garcia KC; Tejpar S; Delorenzi M; Venook AP; Nixon AB; Warren RS; Roose JP; Depeille P
    JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31237864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer.
    Fiala O; Sorejs O; Hosek P; Liska V; Vycital O; Bruha J; Kucera R; Topolcan O; Finek J; Maceckova D; Pitule P
    Cancer Genomics Proteomics; 2020; 17(5):605-613. PubMed ID: 32859639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer.
    Wang Y; Jones JC; Kipp BR; Grothey A
    Ann Oncol; 2019 Jan; 30(1):147-149. PubMed ID: 30364934
    [No Abstract]   [Full Text] [Related]  

  • 14. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
    Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
    Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.
    Ali M; Kaltenbrun E; Anderson GR; Stephens SJ; Arena S; Bardelli A; Counter CM; Wood KC
    Nat Commun; 2017 Jun; 8():15617. PubMed ID: 28593995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.
    Kim N; Cho D; Kim H; Kim S; Cha YJ; Greulich H; Bass A; Cho HS; Cho J
    Int J Cancer; 2020 Apr; 146(8):2194-2200. PubMed ID: 31290142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer.
    Yang L; Bhattacharya A; Li Y; Sexton S; Ling X; Li F; Zhang Y
    J Exp Clin Cancer Res; 2022 Jun; 41(1):184. PubMed ID: 35650607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy.
    Uhlyarik A; Piurko V; Vizkeleti L; Pápai Z; Rásó E; Lahm E; Kiss E; Sikter M; Vachaja J; Kenessey I; Tímár J
    Pathol Oncol Res; 2020 Jul; 26(3):1429-1434. PubMed ID: 30612313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC.
    McGregor M; Price TJ
    Future Oncol; 2018 Oct; 14(24):2437-2459. PubMed ID: 29737864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.